A. H. Brandenburg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
A. H. Brandenburg has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- A. C. G. Voordouw
Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
1 shared publication - Alje Pieter van Dam
Department of Medical Microbiology , Amsterdam UMC Location, University of Amsterdam , Amsterdam , the Netherlands
1 shared publication - Arno Swart
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
1 shared publication - B. J. A. Hoeve-Bakker
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 3721 MA Bilthoven, The Netherlands
1 shared publication - Barbara Bergmans
Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands
1 shared publication Bas Wintermans
Department of Medical Microbiology and Immunology, Admiral De Ruyter Hospital
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (2) , 451-458
Towards harmonization of Lyme diagnostics interpretation: external quality assessment using a web-based survey
Background Laboratory testing plays an important role in diagnosis and clinical management of Lyme borreliosis (LB). While external quality assessments (EQAs) evaluate the technical quality of laboratory diagnostics, the clinical interpretation of laboratory results often remains unassessed. Although specific guidelines are available, different interpretation can result in variations in clinical diagnosis and subsequent management of LB patients. This study aimed to evaluate variations in interpretating LB laboratory diagnostics in relation to the clinical history of the patient. Methods An EQA was organized for medical microbiological laboratories (MMLs) in the Netherlands using a web-based survey. The survey consisted of twenty LB case descriptions including laboratory findings. Participants were asked to (i) interpret each case according to their protocols (open-ended), and (ii) rate the likelihood of the case being active LB (multiple-choice). Six LB diagnostics experts determined the baseline and scored participants’ answers on a 1–10 scale. Results Of the 50 invited MMLs, 38 (76.0%) completed the survey. The overall mean score was 8.8 (range: 7.2 – 9.8). For the multiple-choice questions, the mean score was 9.6 (range: 8.4 – 10) and for open-ended questions this was 8.0 (range: 5.6 – 9.6). Lower scores were obtained for low-incidence manifestations. Conclusions This EQA showed that interpreting LB laboratory results in relation to the clinical information was good and increased awareness among participants to challenges of LB diagnosis and treatment. Training and education could improve interpretation skills. This EQA might be exemplary for future harmonization efforts for (pan-European) clinical evaluation of LB diagnostics. As a potential future approach, supplementing guidelines with an artificial intelligence-based clinical support system could aid medical microbiologists and physicians in decision making, especially for rare manifestations.
- 30 October 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (2) , 451-458
Open AccessTowards harmonization of Lyme diagnostics interpretation: external quality assessment using a web-based survey
Background Laboratory testing plays an important role in diagnosis and clinical management of Lyme borreliosis (LB). While external quality assessments (EQAs) evaluate the technical quality of laboratory diagnostics, the clinical interpretation of laboratory results often remains unassessed. Although specific guidelines are available, different interpretation can result in variations in clinical diagnosis and subsequent management of LB patients. This study aimed to evaluate variations in interpretating LB laboratory diagnostics in relation to the clinical history of the patient. Methods An EQA was organized for medical microbiological laboratories (MMLs) in the Netherlands using a web-based survey. The survey consisted of twenty LB case descriptions including laboratory findings. Participants were asked to (i) interpret each case according to their protocols (open-ended), and (ii) rate the likelihood of the case being active LB (multiple-choice). Six LB diagnostics experts determined the baseline and scored participants’ answers on a 1–10 scale. Results Of the 50 invited MMLs, 38 (76.0%) completed the survey. The overall mean score was 8.8 (range: 7.2 – 9.8). For the multiple-choice questions, the mean score was 9.6 (range: 8.4 – 10) and for open-ended questions this was 8.0 (range: 5.6 – 9.6). Lower scores were obtained for low-incidence manifestations. Conclusions This EQA showed that interpreting LB laboratory results in relation to the clinical information was good and increased awareness among participants to challenges of LB diagnosis and treatment. Training and education could improve interpretation skills. This EQA might be exemplary for future harmonization efforts for (pan-European) clinical evaluation of LB diagnostics. As a potential future approach, supplementing guidelines with an artificial intelligence-based clinical support system could aid medical microbiologists and physicians in decision making, especially for rare manifestations.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 9 (1) , 1965-1973
Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach
Serology is a crucial part of the public health response to the ongoing SARS-CoV-2 pandemic, but there are still many unknowns. Here, we describe the development, validation and clinical evaluation of a protein micro-array as a quantitative multiplex immunoassay that can identify S and N-directed SARS-CoV-2 IgG antibodies with high specificity and sensitivity and distinguish them from all currently circulating human coronaviruses. The method specificity was 100% for SARS-CoV-2 S1 and 96 % for N antigen based on extensive syndromic (n=230 cases) and population panel (n=94) testing that also confirmed the high prevalence of seasonal human coronaviruses. To assess the potential role of the protein micro-array for both SARS-CoV-2 patient diagnostics and population studies, we evaluated a large heterogeneous COVID-19 cohort (n=330) and found an overall sensitivity of 89% (≥ 21 days post onset symptoms (dps)), which ranged from 86% to 96% depending on severity of disease. For a subset of these patients longitudinal samples were provided up to 56 dps. We observed an absent or delayed, and lower SARS-CoV-2 antibody responses in mild cases. Overall, we present the development and extensive clinical validation of a multiplex human coronavirus serological assay that can be used for syndromic testing, to answer research questions regarding human coronavirus antibody responses, to support SARS-CoV-2 diagnostics where RT-PCR lacks in sensitivity and to evaluate epidemiological developments efficiently and with high-throughput.
- 1 January 2020
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 9 (1) , 1965-1973
Open AccessAccurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach
Serology is a crucial part of the public health response to the ongoing SARS-CoV-2 pandemic, but there are still many unknowns. Here, we describe the development, validation and clinical evaluation of a protein micro-array as a quantitative multiplex immunoassay that can identify S and N-directed SARS-CoV-2 IgG antibodies with high specificity and sensitivity and distinguish them from all currently circulating human coronaviruses. The method specificity was 100% for SARS-CoV-2 S1 and 96 % for N antigen based on extensive syndromic (n=230 cases) and population panel (n=94) testing that also confirmed the high prevalence of seasonal human coronaviruses. To assess the potential role of the protein micro-array for both SARS-CoV-2 patient diagnostics and population studies, we evaluated a large heterogeneous COVID-19 cohort (n=330) and found an overall sensitivity of 89% (≥ 21 days post onset symptoms (dps)), which ranged from 86% to 96% depending on severity of disease. For a subset of these patients longitudinal samples were provided up to 56 dps. We observed an absent or delayed, and lower SARS-CoV-2 antibody responses in mild cases. Overall, we present the development and extensive clinical validation of a multiplex human coronavirus serological assay that can be used for syndromic testing, to answer research questions regarding human coronavirus antibody responses, to support SARS-CoV-2 diagnostics where RT-PCR lacks in sensitivity and to evaluate epidemiological developments efficiently and with high-throughput.